Bayer's New Submission for KERENDIA in Heart Failure Treatment
Bayer has taken a significant step in the treatment of heart failure by submitting a supplemental new drug application (sNDA) to the FDA for KERENDIA (finerenone). This innovative treatment aims to help patients suffering from heart failure with a left ventricular ejection fraction of ?40%. This submission is underpinned by encouraging results from the Phase III FINEARTS-HF trial.
Positive Outcomes from the FINEARTS-HF Trial
Results from this trial have showcased that finerenone can lead to a notable 16% reduction in cardiovascular deaths and heart failure events, marking a critical advancement for patients who have limited treatment options. This trial included almost 6,000 individuals diagnosed with heart failure, and the efficacy of finerenone was evident when compared to placebo in addition to standard treatments.
Understanding Heart Failure and Treatment Gaps
Heart failure is a complex condition affecting approximately 6.7 million adults in the U.S. Among them, a significant number—about 55%—have an ejection fraction of ?40%. The landscape of treatment options remains sparse for these patients, highlighting the urgent need for effective therapies like KERENDIA.
The Significance of KERENDIA
KERENDIA is recognized as the first non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) proven effective in a Phase III study for patients with heart failure. This therapy has previously shown benefits for adults with chronic kidney disease linked to type 2 diabetes, demonstrating its versatility in treating various related conditions.
Details from the FINEARTS-HF Study
The FINEARTS-HF trial was a well-structured study designed to evaluate the effectiveness of finerenone in reducing cardiovascular complications among heart failure patients. Participants were closely monitored, and the trial’s primary endpoint was a composite of cardiovascular death and significant heart failure events. Importantly, the absence of new safety signals was noted, with side effects being similar to those observed in earlier trials.
What Lies Ahead for KERENDIA
Alanna Morris, a key figure in Bayer's medical affairs, expressed hope that KERENDIA could become a cornerstone in the treatment of heart failure, especially given the substantial number of patients seeking effective therapies. The importance of addressing heart failure cannot be understated, as the condition comes with a heavy burden of comorbidities including obesity, diabetes, and chronic kidney disease.
About Bayer and Its Commitment
Bayer has longstanding dedication to improving patient outcomes through innovative therapies. The company continues to explore numerous avenues in cardiovascular and kidney diseases. Its portfolio involves various projects aimed at treating heart failure and chronic kidney disease, supporting Bayer's mission to deliver science for a better life.
Frequently Asked Questions
What is KERENDIA used for?
KERENDIA (finerenone) is used to treat patients with heart failure and chronic kidney disease associated with type 2 diabetes.
What are the main findings from the FINEARTS-HF trial?
The FINEARTS-HF trial found that finerenone reduced the risk of cardiovascular death and heart failure events by 16% compared to placebo.
Who is eligible for treatment with KERENDIA?
KERENDIA is primarily indicated for adults experiencing heart failure with a left ventricular ejection fraction of ?40%.
What are the potential side effects of KERENDIA?
Common side effects include hyperkalemia, hypotension, and the risk of renal issues, which necessitate careful monitoring during treatment.
How does Bayer contribute to cardiovascular health?
Bayer is actively involved in developing therapies for cardiovascular conditions through ongoing research and clinical trials aimed at filling gaps in treatment options.
